当前位置: X-MOL 学术Blood Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2021-12-07 , DOI: 10.1038/s41408-021-00590-5
Roberto Mina 1 , Antonietta Pia Falcone 2 , Sara Bringhen 1 , Anna Marina Liberati 3 , Norbert Pescosta 4 , Maria Teresa Petrucci 5 , Giovannino Ciccone 6 , Andrea Capra 1 , Francesca Patriarca 7 , Delia Rota-Scalabrini 8 , Francesca Bonello 1 , Caterina Musolino 9 , Michele Cea 10 , Renato Zambello 11 , Paola Tacchetti 12 , Angelo Belotti 13 , Claudia Cellini 14 , Laura Paris 15 , Mariella Grasso 16 , Sara Aquino 17 , Lorenzo De Paoli 18 , Giovanni De Sabbata 19 , Stelvio Ballanti 20 , Massimo Offidani 21 , Mario Boccadoro 1 , Federico Monaco 22 , Paolo Corradini 23 , Alessandra Larocca 1
Affiliation  



中文翻译:

在不符合移植条件的新诊断多发性骨髓瘤中,基于 Ixazomib 的诱导方案加 ixazomib 维持治疗:II 期、多臂、随机 UNITO-EMN10 试验。

更新日期:2021-12-07
down
wechat
bug